<h4>Background and aim</h4>High-grade B cell lymphomas with concomitant <i>MYC</i> and <i>BCL2</i> and/or <i>BCL6</i> rearrangements (HGBCL-DH/TH) have a poor prognosis when treated with the standard R-CHOP-like chemoimmunotherapy protocol. This evidence concerns the gene BCL2 and B-cell non-Hodgkin lymphoma.